Our
investigations over the last decade characterizing various
“lifestyle-responsive” domains in proteins revealed an exciting
finding, a new domain. This novel domain, named "HIPi" occurs in
less than 100 human proteins and may be the "Achilles Heel" for several
diseases. In other words, this new domain may be an easy and effective
target for biopharmaceutical agents (mAb, iRNA, etc) to treat many
seemingly diverse diseases.
Proteomic
analysis suggests that the "HIPi" domain may be involved in cell
communication and motility signal transduction pathways. Processes
necessary for development of metastatic cancers, among other diseases.
Surprisingly, this domain occurs in a specific subset of cell cycle
effectors with therapeutic implications for chronic disease including
osteoporosis, dental caries, metastatic cancer (breast, prostate,
lung), cardiovascular disease and autoimmune disorders (Crohn’s). These
novel and exciting investigations are ongoing with US and global
patents to be filed in Q2 2010. These filings will launch a new biotech
subsidiary, HIPi LIFE SCIENCES.